Logo Geneseeq
  • Services
    • Genomic Testing
      • Companion Diagnostic Test
      • Laboratory Developed Tests (LDT)
        • Solid Tumors
        • Hematologic Malignancies
        • Hereditary Cancers
        • Minimal Residual Disease
    • Research Services
      • Platforms
      • DNA Sequencing
      • RNA Sequencing
      • Other Services
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
  • Join Us
  • Contact Us
  • Ch|中文
  • Search

March 25, 2021

Genomic Study Uncovers New Biomarkers for the Efficacy of Immunotherapy in Nasopharyngeal Carcinoma (NPC) Patients 

by Geneseeq

May 13, 2019

New biomarkers to predict patients’ clinical outcomes to ICI therapy in lung cancer

by Thomas Fischer

Logo Geneseeq

1-647-255-1076
1-800-362-0325
info.toronto@geneseeq.com

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

101 College Street
Suite 200, MaRS Centre
South Tower
Toronto, Ontario, M5G 1L7
Canada

© 2023 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences